Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Nov;92(11):996-1000.
doi: 10.1136/adc.2006.115493. Epub 2007 Jul 11.

Polyethylene Glycol 3350 Plus Electrolytes for Chronic Constipation in Children: A Double Blind, Placebo Controlled, Crossover Study

Affiliations
Free PMC article
Randomized Controlled Trial

Polyethylene Glycol 3350 Plus Electrolytes for Chronic Constipation in Children: A Double Blind, Placebo Controlled, Crossover Study

M A Thomson et al. Arch Dis Child. .
Free PMC article

Erratum in

  • Arch Dis Child. 2008 Jan;93(1):93

Abstract

Objectives: To assess the efficacy and safety of polyethylene glycol 3350 plus electrolytes (PEG+E) for the treatment of chronic constipation in children.

Design: Randomised, double blind, placebo controlled crossover trial, with two 2-week treatment periods separated by a 2-week placebo washout.

Setting: Six UK paediatric departments.

Participants: 51 children (29 girls, 22 boys) aged 24 months to 11 years with chronic constipation (lasting > or =3 months), defined as < or =2 complete bowel movements per week and one of the following: pain on defaecation on 25% of days; > or =25% of bowel movements with straining; > or =25% of bowel movements with hard/lumpy stools. 47 children completed the double blind treatment.

Main outcome measures: Number of complete defaecations per week (primary efficacy variable), total number of complete and incomplete defaecations per week, pain on defaecation, straining on defaecation, faecal incontinence, stool consistency, global assessment of treatment, adverse events and physical examination.

Results: The mean number of complete defaecations per week was significantly higher for children on PEG+E than on placebo (3.12 (SD 2.05) v 1.45 (SD 1.20), respectively; p<0.001). Further significant differences in favour of PEG+E were observed for total number of defaecations per week (p = 0.003), pain on defaecation (p = 0.041), straining on defaecation (p<0.001), stool consistency (p<0.001) and percentage of hard stools (p = 0.001). Treatment related adverse events (all mild or moderate) occurred in similar numbers of children on PEG+E (41%) and placebo during treatment (45%).

Conclusions: PEG+E is significantly more effective than placebo, and appears to be safe and well tolerated in the treatment of chronic constipation in children.

Conflict of interest statement

Competing interests: Dr Mike Geraint is an employee of Norgine Ltd. All other authors declare that they have nothing to declare.

Similar articles

See all similar articles

Cited by 16 articles

See all "Cited by" articles

Publication types

Feedback